H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Springworks Therapeutics (NASDAQ:SWTX) Inc on Monday, setting a price target of $87, which is approximately 16.58% above the present share price of $74.63.
Burns expects Springworks Therapeutics Inc to post earnings per share (EPS) of -$0.51 for the fourth quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Springworks Therapeutics, with an average price target of $85.
The analysts price targets range from a high of $87 to a low of $83.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$21.59 million. The company's market cap is $3.77 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 58.6% and a 84.00% success rate.
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.